Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
PET Imaging in Prostate Cancer: Diagnosis, Staging, Response Assessment, and...
share announcement

PET Imaging in Prostate Cancer: Diagnosis, Staging, Response Assessment, and Prognosis

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 10961

Special Issue Editors

Prof. Dr. Kirsten Bouchelouche

E-Mail Website
Guest Editor
Department of Nuclear Medicine & PET-Centre, Aarhus University Hospital, DK-8200 Aarhus, Denmark
Interests: PET/CT in prostate cancer; cardiac PET; nuclear cardiology
Dr. Helle D. Zacho

E-Mail Website
Guest Editor
1. Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital, DK-9000 Aalborg, Denmark
2. Department of Clinical Medicine, Aalborg University, DK-9000 Aalborg, Denmark
Interests: PSMA PET/CT; Prostate cancer; bone metastases; molecular imaging; diagnostic test accuracy-tests; PET/CT
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Prostate cancer is the most frequently diagnosed cancer in men other than skin cancer and the second leading cause of death from cancer in men in Western countries. Therefore, prostate cancer is a major global health care challenge. Due to the recent improvements and advancements in the diagnosis, molecular imaging and treatment, management of prostate cancer patients is extremely complex. Both imaging and therapy of prostate cancer are rapidly expanding fields, with many important developments. Molecular imaging using nuclear medicine modalities plays a crucial and increasingly role in the management of prostate cancer patients. Various positron emission tomography (PET) tracers have been developed and tested, and in the recent years, prostate-specific membrane antigen (PSMA) has become one of the most promising targets in nuclear medicine, both for molecular imaging and therapy. Accurate diagnosis, staging, restaging, and assessment of therapy is of utmost importance for selection of the optimal therapy and the clinical management of prostate cancer patients.

This Special Issue of Diagnostics with focus on “PET Imaging in Prostate Cancer: Diagnosis, Staging, Response Assessment, and Prognosis” encourages submission of recent advancements and developments in PET imaging of prostate cancer, including both PET/CT and PET/MR studies. Authors are invited to submit both preclinical and clinical studies in the field. Clinical studies may include systematic reviews/meta-analysis, retrospective studies, and prospective studies emphasizing the present and future role, and need of PET molecular imaging in primary diagnosis, staging, prognostication, treatment-response, and disease relapse.

Prof. Dr. Kirsten Bouchelouche
Dr. Helle D. Zacho
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • PET/CT
  • PET/MR
  • molecular imaging
  • diagnosis
  • staging
  • prognosis
  • response assessment

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

11 pages, 1147 KiB  
Article
Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by 68Ga-PSMA PET/CT
by Mads T. Christensen, Mads R. Jochumsen, Søren Klingenberg, Karina D. Sørensen, Michael Borre and Kirsten Bouchelouche
Diagnostics 2022, 12(1), 195; https://doi.org/10.3390/diagnostics12010195 - 14 Jan 2022
Cited by 4 | Viewed by 1594
Abstract
Objectives: To explore the existence of new predictors of the 68Ga-Prostate-Specific Membrane Antigen (PSMA) PET/CT detection rate at biochemical recurrence (BCR) and to determine the detection rate of 68Ga-PSMA PET/CT dependent of prostate-specific antigen (PSA) levels. Materials and methods: In total, [...] Read more.
Objectives: To explore the existence of new predictors of the 68Ga-Prostate-Specific Membrane Antigen (PSMA) PET/CT detection rate at biochemical recurrence (BCR) and to determine the detection rate of 68Ga-PSMA PET/CT dependent of prostate-specific antigen (PSA) levels. Materials and methods: In total, 189 PCa patients scanned with 68Ga-PSMA PET/CT for detection of BCR after curatively intended treatment with either radical prostatectomy (n = 153) or radiotherapy (n = 36) were included. Clinicopathological information at the time of diagnosis (PSA, clinical tumor-stage, International Society of Urological Pathology Grade Group and whether 68Ga-PSMA PET/CT was used for primary staging), treatment (RT/RP and histopathology of the prostatectomies), and pre-PET PSA were collected from medical records. Results: Of the 189 68Ga-PSMA PET/CT scans, 103 (54.5%) were positive for BCR of PCa. No significant coherency was observed between detection rate and any clinicopathological variables at diagnosis. Detection rates significantly increased with rising PSA: <0.5 ng/mL = 28%, 0.5 ≤ 1 ng/mL = 39%, 1 ≤ 2 ng/mL = 64%, 2 ≤ 5 ng/mL = 87.5% and ≥5 ng/mL = 97%. Conclusions: The detection rate of PCa recurrence was strongly dependent of pre-PET PSA levels. None of the additional clinical variables acquired during primary staging, prostatectomy pathology reports, nor primary staging imaging modality affected the detection rate. Full article
(This article belongs to the Special Issue PET Imaging in Prostate Cancer: Diagnosis, Staging, Response Assessment, and Prognosis)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

25 pages, 16091 KiB  
Review
PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
by Alexander D. Combes, Catalina A. Palma, Ross Calopedos, Lingfeng Wen, Henry Woo, Michael Fulham and Scott Leslie
Diagnostics 2022, 12(11), 2594; https://doi.org/10.3390/diagnostics12112594 - 26 Oct 2022
Cited by 20 | Viewed by 7056
Abstract
Prostate cancer is the most common cancer and the second leading cause of cancer death in men. The imaging assessment and treatment of prostate cancer has vastly improved over the past decade. The introduction of PSMA PET-CT has improved the detection of loco-regional [...] Read more.
Prostate cancer is the most common cancer and the second leading cause of cancer death in men. The imaging assessment and treatment of prostate cancer has vastly improved over the past decade. The introduction of PSMA PET-CT has improved the detection of loco-regional and metastatic disease. PSMA PET-CT also has a role in the primary diagnosis and staging, in detecting biochemical recurrence after curative treatment and in metastasis-directed therapy. In this paper we review the role of PSMA PET-CT in prostate cancer. Full article
(This article belongs to the Special Issue PET Imaging in Prostate Cancer: Diagnosis, Staging, Response Assessment, and Prognosis)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

3 pages, 407 KiB  
Interesting Images
PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
by Peter Iversen, Allan Kjeldsen Hansen, Thorbjørn Hubeck-Graudal, Lise Medrud and Kirsten Bouchelouche
Diagnostics 2022, 12(2), 227; https://doi.org/10.3390/diagnostics12020227 - 18 Jan 2022
Viewed by 1697
Abstract
A 76-year-old man with newly diagnosed high-risk prostate cancer was referred for primary staging with F-18-PSMA-1007 PET/CT. The PET/CT scan showed no lymph node or bone metastases, only localized disease within the prostate gland. Additionally, the F-18-PSMA PET/CT scan showed a PSMA-positive lesion [...] Read more.
A 76-year-old man with newly diagnosed high-risk prostate cancer was referred for primary staging with F-18-PSMA-1007 PET/CT. The PET/CT scan showed no lymph node or bone metastases, only localized disease within the prostate gland. Additionally, the F-18-PSMA PET/CT scan showed a PSMA-positive lesion correlating to a polyp located in the body of the stomach on the greater curvature. A prior F-18-FDG PET/CT showed low FDG uptake in the polyp, but this was not reported initially in the written report. The patient had no upper gastrointestinal symptoms. A gastroscopy with biopsies was performed, and the histopathology results showed chronic unspecific inflammation with no granulomas, dysplastic or malignant changes in three out of three biopsies. A repeated gastroscopy with biopsy showed an epithelioid variant of a gastrointestinal stromal tumor (Ki-67 index 2%). A laparoscopic tumor extirpation was planned after radiation treatment in combination with endocrine therapy of the localized prostate cancer. To our knowledge, this is one of very few reported cases of a PSMA-positive gastrointestinal stromal tumor (GIST), and can be added to the list of malignant pitfalls of PSMA PET/CT in prostate cancer patients. Full article
(This article belongs to the Special Issue PET Imaging in Prostate Cancer: Diagnosis, Staging, Response Assessment, and Prognosis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop